Bellerophon Therapeutics, Inc (BLPH)

Etorro trading 970x250
Bellerophon Therapeutics, Inc (BLPH) Logo

About Bellerophon Therapeutics, Inc

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Address: 184 Liberty Corner Road, Warren, NJ, United States, 07059

Bellerophon Therapeutics, Inc News and around…

Latest news about Bellerophon Therapeutics, Inc (BLPH) common stock and company :

Bellerophon Therapeutics: Q2 Earnings Insights
15 Aug, 2022 FinancialContent

Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's ...

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
15 Aug, 2022 Yahoo! Finance

WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022. “The Bellerophon team continues to advance our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstitial lun

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
27 Jul, 2022 FinancialContent

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a ...

Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
29 Jun, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its ...

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
28 Jun, 2022 FinancialContent

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court ...

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
27 Jun, 2022 FinancialContent

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. Acutus ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
18 May, 2022 FinancialContent

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 15.2% to $0.22 during Wednesday's regular session. ...

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
17 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA May Authorize ...

Buying Power of Bitcoin vs. Bellerophon Therapeutics at New 52-Week High
16 May, 2022 FinancialContent

Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
12 May, 2022 Yahoo! Finance

WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American Thoracis Society (ATS) 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA. Presentation Details Session C103: It's not just about IPFPoster Title: A Phase 2 Trial of INOpulse in

Recap: Bellerophon Therapeutics Q1 Earnings
11 May, 2022 FinancialContent

Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors ...

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
11 May, 2022 Yahoo! Finance

WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on the continued advancement of our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstit

90 Biggest Movers From Yesterday
10 May, 2022 FinancialContent

Gainers Hemisphere Media Group, Inc(NASDAQ: HMTV) shares climbed 78.8% to close at $6.74 on Monday after the company ...

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
31 Mar, 2022 Yahoo! Finance

WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021. “The development of our INOpulse® inhaled nitric oxide therapy platform remains our foremost priority, in order to address the significant unmet needs in fib

Analysts Anticipate IWC To Hit $194
28 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $194.44 per unit.

We Think Bellerophon Therapeutics (NASDAQ:BLPH) Needs To Drive Business Growth Carefully
02 Mar, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

VTI's Holdings Could Mean 10% Gain Potential
16 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $248.22 per unit.

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
10 Jan, 2022 Yahoo! Finance

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022. The Company’s presentation will be available on-demand

12 Health Care Stocks Moving In Thursday's Pre-Market Session
06 Jan, 2022 FinancialContent

Gainers Freeline Therapeutics (NASDAQ:FRLN) stock increased by 58.1% to $3.1 during Thursday's pre-market session. ...

12 Health Care Stocks Moving In Thursday's After-Market Session
23 Dec, 2021 FinancialContent

Gainers Tempest Therapeutics (NASDAQ:TPST) shares increased by 8.19% to $6.6 during Thursday's after-market session. The company's ...

32 Stocks Moving In Wednesday's Mid-Day Session
22 Dec, 2021 FinancialContent

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 31.7% to $2.41 after the company announced it was awarded a multiple ...

65 Biggest Movers From Yesterday
21 Dec, 2021 FinancialContent

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported ...

38 Stocks Moving In Monday's Mid-Day Session
20 Dec, 2021 FinancialContent

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell ...

Mid-Morning Market Update: Markets Open Lower; Carnival Reports Downbeat Q4 Revenue
20 Dec, 2021 FinancialContent

Following the market opening Monday, the Dow traded down 1.58% to 34,806.55 while the NASDAQ fell 1.40% to 14,956.74. The S&P also ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
20 Dec, 2021 FinancialContent

Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
20 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

25 Stocks Moving in Monday's Pre-Market Session
20 Dec, 2021 FinancialContent

Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to ...

63 Biggest Movers From Friday
20 Dec, 2021 FinancialContent

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on ...

12 Health Care Stocks Moving In Friday's After-Market Session
17 Dec, 2021 FinancialContent

Gainers GBS (NASDAQ:GBS) stock rose 14.28% to $1.44 during Friday's after-market session. At the close, GBS's ...

Mid-Afternoon Market Update: Crude Oil Drops Over 2%; Bottomline Technologies Shares Spike Higher
17 Dec, 2021 FinancialContent

Toward the end of trading Friday, the Dow traded down 0.87% to 35,585.26 while the NASDAQ rose 0.43% to 15,245.07. The S&P also ...

Bellerophon Therapeutics, Inc (BLPH) is a NASDAQ Common Stock listed in , ,

970x250